Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany

European Journal of Health Economics

Volumn 10, Issue 1, 2009, Pages 65-79

  Schürmann, Dirk ^a   Sorensen, Sonja V ^b   De Cock, Erwin ^c   Duttagupta, Sandeep ^d   Resch, Ansgar ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c United BioSource Corporation   (Spain)

^d PFIZER INC   (United States)

Author keywords

Complicated skin and soft tissue infections; Cost effectiveness; Linezolid; MRSA; Vancomycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CARBAPENEM; CEFUROXIME; CLINDAMYCIN; COTRIMOXAZOLE; LINEZOLID; OXACILLIN; RIFAMPICIN; VANCOMYCIN;

ABSCESS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SKIN DISEASE; CELLULITIS; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; DIARRHEA; DRUG COST; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEVER; GERMANY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; INTERVIEW; KIDNEY FAILURE; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PHLEGMON; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ACETAMIDES; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DELPHI TECHNIQUE; GERMANY; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; VANCOMYCIN;

EID: 58149098799     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-008-0104-7     Document Type: Article

References (43)

1. D. Nathwani S. Moitra J. Dunbar G. Crosby G. Peterkin P. Davey 1998 Skin and soft tissue infections development of a collaborative management plan between community and hospital care Int. J. Clin. Pract. 52 456 460
2. A.D. Tice D. Poretz F. Cook D. Zinner M.J. Strauss 1998 Medicare coverage of outpatient ambulatory intravenous antibiotic therapy: a program that pays for itself Clin. Infect. Dis. 27 1415 1421
3. R.S. Dykhuizen R.J. Trent D.P. Pacitti T.M. Reid J.G. Douglas C.C. Smith 1994 An analysis of 900 consecutive admissions to a regional infection unit J. Infect. 29 189 193
4. D.L. Stevens L.G. Smith J.B. Bruss 2000 Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections Antimicrob. Agents Chemother. 44 3408 3413
5. Swartz, M.N.: Cellulitis and superficial infections. In: Mandell, G., Douglas, R., Bennett, J. (eds.) Principles and Practice of Infectious Diseases-1990, pp. 796-807. Churchill Livingstone, New York (1992)
6. M. Raghavan P.K. Linden 2004 Newer treatment options for skin and soft tissue infections Drugs 64 1621 1642
7. E.W. Tiemersma S.L. Bronzwaer O. Lyytikainen 2004 Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002 Emerg. Infect. Dis. 10 1627 1634
8. M.E. Jones J.A. Karlowsky D.C. Draghi C. Thornsberry D.F. Sahm D. Nathwani 2003 Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy Int. J. Antimicrob. Agents 22 406 419
9. Paul-Ehrlich-Gesellschaft fur Chemotherapie: http://www.p-e-g.org/ ag_resistenz/main.html. Accessed 01 Feb 2006
10. S.E. Cosgrove G. Sakoulas E.N. Perencevich M.J. Schwaber A.W. Karchmer Y. Carmeli 2003 Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis Clin. Infect. Dis. 36 53 59
11. T.P. Lodise P.S. McKinnon 2005 Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia Diagn. Microbiol. Infect. Dis. 52 113 122
12. S.D. Reed J.Y. Friedman J.J. Engemann 2005 Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia Infect. Control Hosp. Epidemiol. 26 175 183
13. A. Voss D. Milatovic C. Wallrauch-Schwarz V.T. Rosdahl I. Braveny 1994 Methicillin-resistant Staphylococcus aureus in Europe Eur. J. Clin. Microbiol. Infect. Dis. 13 50 55
14. Centers for Disease Control and Prevention. 1997 Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997 MMWR 46 813 815
15. A.L. Panlilio D.H. Culver R.P. Gaynes 1992 Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991 Infect. Control Hosp. Epidemiol. 13 582 586
16. M.C. Ploy C. Grelaud C. Martin L. de Lumley F. Denis 1998 First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital Lancet 351 1212
17. S.S. Wong P.L. Ho P.C. Woo K.Y. Yuen 1999 Bacteremia caused by staphylococci with inducible vancomycin heteroresistance Clin. Infect. Dis. 29 760 767
18. G.M. Eliopoulos C.B. Wennersten H.S. Gold R.C. Moellering Jr 1996 In vitro activities in new oxazolidinone antimicrobial agents against enterococci Antimicrob. Agents Chemother. 40 1745 1747
19. C.W. Ford J.C. Hamel D.M. Wilson 1996 In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections Antimicrob. Agents Chemother. 40 1508 1513
20. S.M. Swaney H. Aoki M.C. Ganoza D.L. Shinabarger 1998 The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria Antimicrob. Agents Chemother. 42 3251 3255
21. G.E. Zurenko B.H. Yagi R.D. Schaadt 1996 In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents Antimicrob. Agents Chemother. 40 839 845
22. A.Z. Yaldo J.L. Sullivan Z. Li 2001 Factors influencing physicians' decision to discharge hospitalized patients infected with methicillin-resistant Staphylococcus aureus Am. J. Health Syst. Pharm. 58 1756 1759
23. D.L. Stevens D. Herr H. Lampiris J.L. Hunt D.H. Batts B. Hafkin and the Linezolid MRSA Study Group 2002 Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin. Infect. Dis. 34 1481 1490
24. A Vinken Z Li D Balan B Rittenhouse R Wilke D Nathwani 2001 Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytic model J. Hosp. Infect. 49 Suppl A S13 S24
25. G.L. Plosker D.P. Figgitt 2005 Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections Pharmacoeconomics 23 945 964
26. J. Weigelt K. Itani D. Stevens 2005 Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections Antimicrob. Agents Chemother. 49 2260 2266
27. P.S. McKinnon S.V. Sorensen L.Z. Liu K.M. Itani 2006 Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections Ann. Pharmacother. 40 1017 1023
28. K.M. Itani J. Weigelt J.Z. Li S. Duttagupta 2005 Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA) Int. J. Antimicrob. Agents 26 442 448
29. J. Weigelt H.M.A. Kaafarani K.M.F. Itani R.N. Swanson 2004 Linezolid eradicates MRSA better than vancomycin from surgical-site infections Am. J. Surg. 188 760 766
30. Deutsche Krankenhausgesellschaft Tarif der Deutschen Krankenhausgesellschaft für die Abrechnung erbrachter Leistungen und fur die Kostenerstattung vom Artz an das Krankenhaus DKG-NT Band I. W. Kohlhammer Verlag. Juli 2002
31. Einheitlicher Bewertungsmaßstab (EBM), Stand 1 Oktober 2001, Dienstauflage der Kassenärztlichen Bundesvereinigung, Deutscher Arzte Verlag, Köln (2001)
32. Kassenärztliche Vereinigung Westfalen-Lippe (KVWL): Honorarverteilungsvertrag (2004)
33. Institut für das Entgeltsystem im Krankenhaus gGmbH: Abschlussbericht. Weiterentwicklung des G-DRG-Systems für das Jahr 2004. Klassifikation, Katalog und Bewertungsrelationen. Band II: Fallpauschalen- Katalog, Klinische Profile, Kostenprofile, 19 December 2003. http://inek.customer.msim.de/service/download/Projektbericht2003/ Abschlussbericht_G-DRG_V2004_0312191400_BII.pdf. 01 Feb 2006
34. W. Popp M. Hilgenhoner T. Leisebein H. Muller 2003 Personalkosten durch Isolierungsmassnahmen von MRSA-Patienten Gesundh. Okon. Qual. Manage. 8 187 190
35. Rote Liste® Service GmbH: Rote Liste. http://www.rote-liste.de. 30 June 2004
36. World Health Organization: International statistical classification of diseases and related health problems. In: Tenth Revision, German Modification (ICD-10-GM), Version 2003. German Institute for Medical Documentation and Information, Cologne, Germany (2003)
37. Universitätsklinikum Münster: Westfälische Wilhelms-Universität Münster. Medizincontrolling/DRG Research Group. WebGrouper: G-DRG 2004/2005. http://drg.uni-muenster.de/de/webgroup/m.webgroup. php. 01 Feb 2006
38. A.G. Vinken J.Z. Li D.A. Balan B.E. Rittenhouse R.J. Willke C. Goodman 2003 Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals Am. J. Ther. 10 264 274
39. Z. Li R.J. Willke L.A. Pinto 2001 Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial Pharmacotherapy 21 263 274
40. R. Ono D.J. Wedemeyer 1994 Assessing the validity of the Delphi technique Futures 26 289 304
41. A.M. Walker J. Selfe 1996 The Delphi method: a useful tool for the allied health researcher Br. J. Ther. Rehabil. 3 677 681
42. M.H. Wernitz S. Keck S. Swidsinski S. Schulz S.K. Veit 2005 Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment Clin. Microbiol. Infect. 11 466 471
43. J. Schreyögg T. Stargardt O. Tiemann R. Busse 2006 Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries Health Care Manage. Sci. 9 215 223